- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Navigating Toxicity: Comparing Third-Line mCRC Therapies
Medical experts compare the toxicity profiles of FTD/TPI plus bevacizumab, regorafenib, and fruquintinib, and discuss practical strategies for managing treatment-related toxicities with these third-line therapies.
EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC
EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC
EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2
EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib
EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions
EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions
EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies
EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options
EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care
EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights
Video content above is prompted by the following:
- How do the toxicity profiles differ with FTD/TPI plus bevacizumab, as compared with regorafenib or fruquintinib, and how might these different toxicity profiles be leveraged when making treatment selections?
- What are some key, practical strategies you use to manage treatment-related toxicities with these third-line therapies?
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
With Hidradenitis Suppurativa, Maternal and Offspring Outcomes May Suffer
October 31st 2024Novel evidence has emerged from a 16-year study that hidradenitis suppurativa can elevate risks of not only pregnancy and postpartum complications, but of morbidity—particularly metabolic- and immunology-related morbidity—for mother and child in the long term.
Read More
